Xencor

contact sitemap home

Products

• PRODUCTS

• Pipeline
• Clinical Trials

• XmAb™ Antibody Therapeutics

  • XmAb™2513
  • XmAb™5574
  • XmAb™5483
  • XmAb™5871
  • XmAb™ Pipeline Candidates
• XPro™ Protein Therapeutics

XmAb™5574

XmAb™5574 is a humanized monoclonal antibody that targets the antigen CD19 for treatment of B cell malignancies and autoimmune diseases. XmAb™5574 contains a proprietary Xencor XmAb Fc domain that enhances cytotoxic potency and also downregulates B cell activation.

RELATED LINKS

• XmAb™ Technology
• Partnering opportunities

Location Careers Events Publications Articles Press Releases

Copyright © 2005 Xencor, Inc.   All rights reserved.   Designed by